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by
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ABSTRACT
Human African Trypanosomiasis (HAT) and Leishmaniasis are protozoal parasitic
infections. Designated neglected tropical diseases and global in their impact, these diseases afflict
the poorest people in the world. Treatments have remained essentially unchanged for decades and
have poor efficacy and questionable safety profiles. In the first study, seventeen novel 2-[2acylamidoethyl]-6(phenyl)pyridine analogues were designed using a ‘hit to lead’

strategy,

synthesized and submitted for evaluation in vitro against Trypanosoma brucei rhodesiense (T. b.
r.) for potential treatment against second stage HAT. Eight compounds gave T. b. r. IC50 values
of 100nM or less; the best three compounds exhibited values of 64 nM, 12 nM, and 9 nM. In the
second study, four novel N-(4-(5-(4-((5-(1H-azole-1-yl)pentyl)oxy)phenyl)furan-2-yl)phenyl)
picolinimidamide hydrochloride hybrid analogues were designed using a molecular hybridization
strategy for dual targeting, synthesized and submitted for evaluation in vitro against Leishmania.
Four compounds exhibited IC50 values in the low micromolar range.
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PART 1

1
1.1

Introduction

Disease Background
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a disease

caused by unicellular eukaryotic parasitic protozoa of the Trypanosoma brucei subgroup called
trypanosomes1. Various species of the tsetse fly, genus Glossina, are the biological vector of
trypanosomes2. Transmission of this disease occurs through the bite of the infected tsetse fly to
susceptible host only in Sub-Saharan Africa, suitable regions to the tsetse fly habitat vector2. There
are two forms of the disease, T. brucei gambiense and T. brucei rhodesiense, each caused by a
different species of the Trypanosoma brucei subgroup, gambiense and rhodesiense, respectively1.
This study will evaluate compounds against the rhodesiense form.
The incidence of the disease is variable but has shown a clear decrease in both forms over
the past 10 years. In 2009, the number of new cases reported dropped below 10,000 for first time
in 50 years and this trend was maintained in 2010. The estimated number of actual cases is
currently 30,000.3
Epidemiologically, incidence and prevalence of HAT, for both disease forms, are dispersed
in geographically discrete foci of the tsetse fly which often are discontinuous. These foci can be
defined under 4 different contexts divided into 2 areas. Gambiense form includes 3 areas: West
and Central Africa show very low prevalence and the Democratic Republic of the Congo accounts
for over 80% of total HAT cases. Rhodesiense areas include East and Southern Africa and report
less than 200 cases per year accounting for less than 3% of total HAT cases reported.
Approximately 70 million people are estimated to be at different levels of risk of contracting HAT
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in Africa. Due to the discontinuous geographical distribution of the disease, spatially discrete
estimates of population at risk have been calculated and classified in five categories of risk, ranging
from “very high” to “very low” based on information including HAT reported cases and
geographic distribution of human population.3
T. brucei rhodesiense is considered a zoonotic disease and is endemic to eastern subSaharan Africa. The disease develops rapidly upon transmission and can be detected early, but
the condition is fatal if untreated causing death in a matter of weeks or months. The disease
develops through two defined stages: stage one is defined as the haemolymphatic stage and
involves trypanosomes in the haemolymphatic system while in stage two, defined as the meningoencephalitic stage (or late stage), the parasite has crossed the blood brain barrier to invade the CNS
causing deterioration of neural tissue with subsequent symptoms including coma, disruption to
sleep/wake patterns referred to as ‘sleeping sickness’, and death if untreated.1 This study will focus
on the design and synthesis of 2-[2-acylamidoethyl]-6-phenyl pyridines for the purpose of treating
second stage HAT.
1.2

Current Drug Treatments
Currently four compounds are registered for use against HAT; two are used for first stage,

haemolymphatic stage, disease (suramin and pentamidine, Fig 1) and two are used against second
stage, meningoencephalitic stage, disease (melarsoprol and eflornithine, Fig 2).
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Figure 1 Structure of Suramin and Pentamidine.

Figure 2 Structure of Melarsoprol and Eflornithine.

Pentamidine, first used in 1940, is the first-line treatment for early stage T. b. gambiense
HAT. Although generally tolerated, undesirable side effects include hypoglycemia, prolongation
of the QT interval on electrocardiogram, hypotension and gastrointestinal features.1 Suramin,
discovered in 1921, is the first-line treatment for early stage T. b. rhodesiense HAT. Although
effective, especially if administered early in the disease, undesirable side effects include renal
failure, skin lesions, anaphylactic shock, bone marrow toxicity and neurological complications
such as peripheral neuropathy.1
Treatment for second stage HAT is more problematic as drugs must pass the blood-brain
barrier to reach the parasite. Administration and toxicity of drugs for late stage HAT are also
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among the problematic variables. Presently, melarsoprol, which acts on trypanothione, a parasite
molecule that maintains an intracellular reducing environment, is the only effective drug available
for treatment of late-stage T. b. rhodesiense HAT and is the most widely used treatment for T. b.
gambiense HAT in resource poor countries where eflornithine has limited availablity. However,
melarsoprol is a toxic trivalent organoarsenic compound and undesirable side effects include
encephalopathy, leading to a 5% fatality rate through treatment with this drug. Due to melarsoprol
resistance in Central Africa, eflornithine, an ornithine decarboxylase inhibitor, has been designated
as an effective treatment for late-stage T. b. gambiense HAT. All of these drugs are administered
by injection and have undesirable side effects. Thus, the need for new drugs to treat diseases
caused by this parasite is evident.1
1.3

Drug Discovery Strategies – In the Absence of a Known Target
Current drug discovery strategies are generally based on identification and validation of

biological targets which participate in the pathogenesis of the disease. Drug candidates can then
be tested for activity on these targets and optimization of the candidate molecules typically
follows.3 However, in this study, the target is unknown. In this case, an effective drug discovery
strategy, called a structure modification ‘hit-to-lead’ strategy, involves defining a ‘hit’ for a
putative target of unknown structure and allowing the ‘hit’ and optimized derivatives thereof,
called a hit series, to define the active site of the putative unknown target.
This study focuses on the design and synthesis of analogues of N-(2-(6-phenylpyridin-2yl)ethyl)benzamide which will be referred to as the hit compound (Fig 3), a compound discovered
by our laboratory to be active against T. b. r. 4.
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Figure 3 Structure of N-(2-(6-phenylpyridin-2-yl)ethyl)benzamide.

A small structure activity relationship (SAR) study was performed previous to this study,
demonstrating important structural features of the hit molecule 4. Figure 4 illustrates various
structural modifications of the pyridylethylamide analog hit series, establishing the necessary
structural features for target compounds to provide activity against T. b. r. Allowing the hit
molecule to serve as the reference, a significant loss in activity is observed by placing the 2pryidylethylamido substituent at the 3-pyridyl position (DB 2141) as the T. b. r. IC

50

value

increases from 0.66 to 20.0 μM. An essentially equal loss in activity is observed when removing
the nitrogen from the heterocycle (DB 2068) with the T. b. r.

IC 50 value increasing to 19.8 μM.

Substituent modifications to the left terminus of the pyridyl nucleus demonstrate significant loss
in activity as observed by altering the 6-phenylpyridyl substituent to the 5-pyridyl position (DB
2140) with T. b. r. IC50 increasing to 12.8 μM, however, the largest loss in activity is observed
with the removal of the 6-phenylpyridyl substituent (DB 2139) with T. b. r. IC 50 value increasing
to above 90 μM. In evaluating structural modifications of this hit series, this SAR study assists in
defining the size, shape, and functionality of the putative active site. The hit molecule was
discovered to have good activity against T. b. r. with an IC50 value of 0.66 μM.

6

Figure 4 SAR previously establishing the hit molecule N-(2-(6-phenylpyridin-2-yl)ethyl)benzamide.4

1.4

Statement of Problem
Modifications of the hit compound are explored in a systematic fashion for the purpose of

improving the activity against T. b. r. and ultimately treating late stage HAT. In general terms one
varies the size, shape and functionality, which can participate in intermolecular interactions, of the
hit molecule to learn what structural features are important for biological activity. In this study,
we vary the structure of the pyridylethylamide analogs by altering the terminal positions while
conserving the central pryidylethylamide nucleus-scaffold. It is desirable to focus on molecules
with “drugable” physiochemical properties early in the hit-to-lead progress. To treat second stage
HAT, it is important to design molecules with calculated polar surface areas approximately in the
range of 50 to 90 and calculated log P values in the range of 2 - 3.5 to enhance the possibility of
the compounds penetrating the blood-brain barrier 5.
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2

Results and Discussion

2.1 Results
Our study to vary the structure of the pyridylethylamide analogs by altering the terminal
positions is summarized in Schemes 1 and 2. The approaches to the synthesis of these analogues
are relatively short and readily performed. Schemes 1 and 2 outline the approach to the synthesis
of 2-[2-acylamidoethyl]-

6(phenyl)pyridine analogues (7a-k & 10a-g). The first step in the

synthesis of the various amide

derivatives employs nucleophilic displacement of one

bromide from 2,6 di-bromopyridine by the anion of tert-butyl cyanoacetate under moderate
conditions, which we have previously

extensively used 6.

2,6-Dibromopyridine (1) was

stirred with 1.1 equivalents of tert-butyl cyanoacetate (2) and 2 equivalents of potassium carbonate
in dimethylformamide under nitrogen atmosphere at 80 C for 24 h to afford the resulting
monosubstituted tert-butyl cyanoacetate analogue (3).

This compound was then directly

converted to the acetonitrile analogue (4) by heating under reflux in toluene in the presence of a
catalytic amount of p-toluene sulfonic acid. Suzuki coupling between the nitrile

and

various

boronic acids in the presence of 0.05 equivalents of Pd(PPh3)4 using a solvent mixture of tolueneethanol afforded compound (5) in the second step of

this

synthesis.

The

resulting

substituted pyridyl acetonitrile was then stirred in the presence of LiAlH4 and AlCl3 in ether and
allowed to reflux 24 h providing the corresponding substituted pyridyl ethylamine (6). One
equivalent of the primary amine was used directly in the last step in

the presence of 1.13

equivalents of the appropriate carboxylic or carbonyl chlorides, a catalytic amount of triethylamine
in anhydrous dichloromethane, and allowed to stir under nitrogen atmosphere at room temperature
to afford the target compounds (7a-k & 10a-g).
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Scheme 1 Synthesis of 2-[2-acylamidoethyl]-6(phenyl)pyridine analogues

Reagents and conditions (a) (i) K2CO3, DMF, 80° C (ii) HCl; (b) p-toluene sulphonic acid, Toluene, reflux
(iii) Na2CO3; (c) Phenylboronic acid, Pd(PPh3)4, Na2CO3, Toluene, C2H5OH; (d) LiAlH4, AlCl3, Et2O,
reflux; (c) various carboxylic and carbonyl chlorides, Et3N, CH2Cl2, anhydrous, rt.
Scheme 2 Synthesis of 2-[2-acylamidoethyl]-6(phenyl)pyridine analogues

Reagents and conditions (a) various boronic acids, Pd(PPh3)4, Na2CO3, dioxane, C2H5OH, 100 C; (b)
LiAlH4, AlCl3, reflux; (c) carbonyl chloride, Et3N, CH2Cl2, anhydrous, rt.

9
Table 1 Biological Activity of 2-[2-acylamidoethyl]-6(phenyl)pyridine analogues7

Code Code 2
1

a

R1

7a
7i
7b

DB2084 phenyl
DB2230 phenyl
DB2233 phenyl

7g

DB2245 phenyl

7f

DB2225 phenyl

7h

DB2234 phenyl

7c

DB2256 phenyl

7e

DB2257 phenyl

7d

DB2281 phenyl

7j
7k
10a
10b
10c
10d
10e
10f
10g

DB2222
DB2221
DB2283
DB2282
DB2271
DB2270
DB2273
DB2274
DB2280

phenyl
phenyl
2-F-phenyl
2-F-phenyl
3-F-phenyl
3-F-phenyl
4-F-phenyl
4-F-phenyl
3,4-Fphenyl

R2
phenyl
c-hexyl
2-Fphenyl
2-Clphenyl
2,6-di-Fphenyl
2,6-di-Clphenyl
3-Fphenyl
2,3-di-Fphenyl
4-Fphenyl
pyrolidine
piperidine
pyrolidine
piperidine
pyrolidine
piperidine
pyrolidine
piperidine
pyrolidine

T. b. r.
IC50
(M)
0.660
0.280
0.720

Cytotox
IC50
(M)
196
>292
158

SI

tPSA

ClogP

299
1040
219

41.5
41.5
41.5

3.56
3.65
3.49

1.16

123

106

41.5

3.64

4.61

111

24.0

41.5

3.29

16.2

87.8

5.40

41.5

3.60

0.231

104

450

41.5

3.90

1.82

118

65.0

41.5

3.64

0.113

71.1

629

41.5

3.90

0.103
0.052
0.076
0.240
0.041
0.012
0.064
0.024
0.009

168
226
245
165
160
161
185
166
139

1630
4350
3220
688
3900
13400
2890
6920
16200

49.1
49.1
49.1
49.1
49.1
49.1
49.1
49.1
49.1

2.76
3.21
2.92
3.48
2.92
3.48
2.92
3.48
3.56

The in vitro activities were obtained using the trypomastigote bloodstream form of T. brucei
rhodesiense strain. The IC50 values are the mean of two independent assays. Coefficients of
variation were less than 50% 7.
b
Cytoxicity was evaluated using cultured L6 rat myoblast cells. were generated in an in-vitro
assay.7
c
ClogP and tPSA values were calculated using ChemBioDrawUltra 2010 software.
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2.2

Discussion
Evaluation of biological activity for 2-[2-acylamidoethyl]-6(phenyl)pyridine analogues

(7a-j & 10a-g) allows for interpretation of binding specificities for a putative active site of an
unknown target. To investigate the tolerance of the active site for specificity of binding, various
derivatives of N-(2-(6-phenylpyridin-2-yl)ethyl)benzamide (7a), the hit compound, were explored
by varying the 6-phenylpyridyl and amide substituents. Table 1 contains the results for the
biological evaluation for all these compounds.
Compounds 7a-7i explore the effectiveness of change at the amide phenyl site of 7a.
Various halogen substituents on the phenyl ring were studied (7b-7h) and the activity was
increased only with 7c and 7d with a fluorine atom in the m and p positions. The most active
compound of this set, 7d, is about six fold more active than the parent 7a. Replacement of the
phenyl with a cyclohexyl group, 7i, increased the activity by a factor of approximately two.
Replacement of the phenyl group of the amide unit with pyrrolidine or piperidine rings,
thus converting the amide unit to a urea one, gives compounds 7j and 7k. The

T. b. r. IC50 value

for 7j is 100 nM and it shows low cytotoxicity, with a selectivity index of 2264. When compared
to the hit 7a, this represents a six fold improvement in activity and ten-fold improvement in
cytotoxicity. Compound 7k has a T. b. r. IC50 value of 50 nM and selectivity index of 3358 which
represents a further increase in activity and lowering of cytotoxicity. It is possible that the amide
carbonyl group of 7a serves as a hydrogen bond acceptor at the receptor binding site. Thus, the
increase in activity of 7j and 7k may be due to the formation of a stronger hydrogen bond as a
result of the more basic urea carbonyl groups. Due to the nanomolar T. b. r. activity and the
excellent selectivity indices of 7j and 7k, the urea moiety was conserved for the remainder of the
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study. From this point the pyrolidine 7j and piperidine 7k with T. b. r. IC50 values of 100 and 50
nm respectively will be referenced as the urea parent compounds.
On substituting fluorine for hydrogen in the ortho position of the 6-phenylpyridyl
substituent (10a & 10b) of the urea parent compound, a modest decrease of T. b. r. IC50 is observed
with pyrolidine substituted at the amide site (10a) and a larger decrease of T. b. r. IC50 observed
with piperidine substituted at the amide site (10b).
However, substitution of fluorine for hydrogen in the meta positions of the 6-phenylpyridyl
substituent and pyrolidine and piperidine at the amide site (10c & 10d) results in a decrease in T.
b. r. IC50, increasing activity to values of 41 nM and 12 nM respectively. Substitution of fluorine
in the para positions also results in an increase of activity with piperidine as the amide substituent
(10f) showing T. b. r. IC50 of 24 nM. A more modest increase in T. b. r. IC50 to 64 nM is observed
with the pyrolidine analogue (10c).
Substitution of hydrogen with a fluorine in both the m and p positions in the 6phenylpyridyl substituent and with piperidine at the amide site (10g) results in the most active
compound of the series showing a significant increase in activity giving a T. b. r. IC50 value of 9
nM and giving an impressive selectivity index of greater than 16,000.
The ClogP values for all the F-substituted analogues are slightly higher than the parent urea
compounds. This modest increase in hydrophobicity may contribute to the increased activity of
these analogues, perhaps due to better uptake by the trypanosomes.
There is an apparent trend of increased activity of piperidine at the urea position. The three
most active compounds from this study, 10g, 10d, 10f, are substituted with piperidine at the amide
site. The low nanomolar T. b. r. activity and excellent selectivity indices of 10g, 10d and 10f merit
in vivo evaluation of these compounds to determine if further work on this series is warranted.
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3

Experimental

All commercial reagents were used without purification. Melting points were determined
on a Mel-Temp 3.0 apparatus and are uncorrected. TLC analysis was carried out on silica gel 60
F254 pre-coated aluminum sheets using UV light for detection.

1

H,

13

C, and

19

F NMR were

recorded on a Bruker 400 MHz spectrometer using the indicated solvents. 1H NMR were recorded
using a frequency of 400 MHz,

13

C NMR 100.6 MHz, and

19

F NMR 376.5 MHz. Mass spectra

were obtained from the Georgia State University Mass Spectrometry Laboratory, Atlanta, GA.
Elemental analysis was performed by Atlantic Microlab Inc., Norcross, GA.

tert–Butyl 2-(6-bromopyridin-2-yl)-2-cyanoacetate (JD-1-7, 3).

A mixture of the

dibromo compound (1) (30 g, 126.64 mmol), tert-butyl cyanoacetate (2) (19.18 ml, 134.20 mmol)
and K2CO3 (35 g, 253.28 mmol) in anhydrous DMF (75 ml) was stirred at 80 C under nitrogen
atmosphere for 24 h. The mixture was diluted with ice, acidified with conc. HCl to pH 1, and
extracted with ethyl acetate. The organic layer was separated, washed with water, dried (MgSO4),
filtered and concentrated in vacuo to provide tert–butyl 2-(6-bromopyridin-2-yl)-2-cyanoacetate
as a yellow solid (26.95g, 72%, 3). This compound was used directly in the next step.
2-(6-Bromopyridin-2-yl)acetonitrile (JD-1-10, 4). Tert–butyl 2-(6-bromopyridin-2-yl)2-cyanoacetate (3) (26.95g, 90.69 mmol) was dissolved in toluene (200 ml), and p-toluene
sulphonic acid monohydrate (1.0 gm) was added. The mixture was heated under reflux for 12 h
and then cooled to room temperature. The toluene was decanted, the black residue was extracted
with ethyl acetate, and the two organic phases were combined, neutralized with NaHCO3 solution
(75 ml), dried (MgSO4), filtered and concentrated in vacuo. The product was purified by column
chromatography on silica gel using hexanes/ethyl acetate (70/30, v/v) as eluent to provide 2-(6-

13

bromopyridin-2-yl)acetonitrile as a yellow solid (5.7 gm, 36 %, 4) mp = 46.5-48.5 C (reported
46-46.5 C).6

1

H NMR (CDCl3):  7.64-7.6 (m, 1 H), 7.49-7.46 (m, 2 H), 3.95 (s, 2 H); 13C NMR

(CDCl3):  150.6, 141.1, 138.7, 126.8, 120.1, 115.3, 25.2.
2-(6-Phenylpryidin-2-yl)acetonitrile (JD-1-14 &15, 5) Phenyl boronic acid (4.08g,
35.78 mmol) was added to a solution of 2-(6-bromopyridin-2-yl) acetonitrile (4.7g, 23.85 mmol)
in 1,4-dioxane (35 ml) and de-airated under nitrogen atmosphere. A 2 M aqueous solution of
Na2CO3 (35.8 ml, 71.55 mmol), ethanol (8 ml) and tetrakistriphenylphosphine palladium(0) (1.42
g, 1.19 mmol) were added to the de-airated reaction mixture and allowed to stir overnight at 100C
under nitrogen atmosphere. The reaction mixture was cooled to room temperature, separated with
ethyl acetate, dried (MgSO4), filtered and concentrated in vacuo. The product was purified by
column chromatography on silica gel using hexanes/ethyl acetate (70/30 v/v) as eluent to provide
2-(6-phenylpryidin-2-yl)acetonitrile as a white solid (3.61g, 78%, 5) mp = 78-78.5C (reported
80-80.5 C).6 1H NMR (CDCl3):  8.16-8.14 (m, 2 H), 7.82-7.80 (m, 2 H ), 7.51-7.49 (m,2 H),
7.40 (s, 1H), 7.28 (s, 1 H 0, 4.03 (s, 2 H); 13C NMR (CDCl3):  159.8, 156.3, 149.1, 136.9, 130.0,
127.3, 117.9, 116.3, 113.3, 113.1, 25.9; ESI-HRMS: m/z calculated for C13H10N2: 195.0924,
found: 195.0922.
2-(6-Phenylpyridin-2-yl)ethan-1-amine (JD-1-16, 6). Lithium aluminum hydride (190
mg, 4.99 mmol) suspended in ethyl ether (10 ml) was added to a slurry of aluminum chloride (670
mg, 4.99 mmol) in ethyl ether (15 ml). The reaction mixture was stirred for 15 min., after which
2-(6-phenylpryidin-2-yl)acetonitrile (970 mg, 4.99 mmol) dissolved in ethyl ether (15 ml) was
added slowly, and the reaction mixture was refluxed under nitrogen atmosphere overnight. The
reaction mixture was then cooled to room temperature and quenched slowly with water (9 ml),
basified with 5 N sodium hydroxide, and extracted with ethyl ether (2 X 50 ml), dried (MgSO4),
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filtered and concentrated in vacuo to provide 2-(6-phenylpyridin-2-yl)ethan-1-amine (0.78g, 79%)
as a yellow oil which was used directly in the next step.
2-Fluoro-N-[2-(6-phenylpyridine-2-yl)ethyl]benzamide (DB2233, JD-1-26, 7b).

2-

Fluorobenzoyl chloride (610 mg, 3.82 mmol) was added to a mixture of 2-(6-phenylpyridin-2yl)ethan-1-amine (670 mg, 3.38 mmol), triethylamine (0.520 ml, 3.72 mmol) and anhydrous
dichloromethane (15 ml). The reaction mixture was allowed to stir at room temperature overnight
under nitrogen atmosphere. The residue was purified by column chromatography on silica gel
with hexanes/ethyl acetate (9:1) as eluent providing 2-fluoro-N-[2-(6-Phenylpyridine-2yl)ethyl]benzamide as a white solid (240 mg, 20%); mp = 114-116 C. 1H NMR (DMSO-d6 /D2O ):
 8.02 (d, J = 7.0 Hz, 2 H), 7.78-7.72 (m, 2 H), 7.56-7.40 (m, 5 H), 7.25-7.20 (m, 3 H), 3.69 (t, J
= 6.5 Hz, 2H), 3.05 (t, J = 6.5 Hz, 2H); 19F NMR (DMSO-d6 / Hexaflurobenzene):  -116.70 (s),
-164.90 (s); ESI: m/z calculated for C20H17FN2O: 320.3602, found: 320.1403. Anal. Calcd for
C20H17 FN2O + (0.15 OH2): C, 74.98; H, 5.35; N, 8.74. Found: C, 74.53; H, 5.31; N, 8.59.
3-Fluoro-N-[2-(6-phenylpyridine-2-yl)ethyl]benzamide (DB2256, JD-1-31, 7c).

3-

Fluorobenzoyl chloride (776 mg, 4.90 mmol) was added to a mixture of 2-(6-phenylpyridin-2yl)ethan-1-amine (860 mg, 4.34 mmol), triethylamine (0.670 ml, 4.77 mmol) and anhydrous
dichloromethane (20 ml). The reaction mixture was allowed to stir at room temperature overnight
under nitrogen atmosphere. The residue was purified by column chromatography on silica gel
with hexanes/ethyl acetate (9:1) as eluent providing 3-fluoro-N-[2-(6-phenylpyridine-2yl)ethyl]benzamide as a white solid (440 mg, 28%); mp = 79.5-80.5 C. 1H NMR (DMSO-d6): 
8.00 (d, J = 7.0 Hz, 2 H), 7.76-7.73 (m, 2 H), 7.62-7.51 (m, 2 H), 7.46-7.38 (m, 4 H), 7.32-7.21
(m, 2H), 3.66 (t, J = 6.5 Hz, 2 H), 3.04 (t, J = 6.5 Hz, 2 H);
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F NMR (DMSO-d6 /

Hexaflurobenzene):  -115.22 (s), -164.90 (s); ESI: m/z calculated for C20H17FN2O: 320.3602,
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found: 320.1403. Anal. Calcd for C20H17 FN2O: C, 74.98; H, 5.35; N, 8.74. Found: C, 75.22; H,
5.15; N, 8.71.
4-Fluoro-N-[2-(6-phenylpyridine-2-yl)ethyl]benzamide (DB2281, JD-1-70, 7d).

4-

fluorobenzoyl chloride (0.256 g, 1.62 mmol) was added to a mixture of 2-(6-phenylpyridin-2yl)ethan-1-amine (0.285 g, 1.44 mmol), triethylamine (220 ml, 1.58 mmol) and anhydrous
dichloromethane (30 ml). The reaction mixture was allowed to stir at room temperature overnight
under nitrogen atmosphere. The residue was purified by column chromatography on silica gel
with hexanes/ethyl acetate (4:1, 3:1, 2:1, 1:1) as eluent providing 4-fluoro-N-[2-(6-phenylpyridine2-yl)ethyl]benzamide as a white solid (279 mg, 60.5%); mp = 76 - 78 C. 1H NMR (DMSO-d6
/D2O): d, J = 7.0 Hz, 2H), 7.78-7.72 (m, 2H), 7.47-7.40 (m, 4H), 7.23 (d, J = 7.5 Hz, 1H),
7.08 (t, J = 7.5 Hz, 2H), 3.68 (t, J = 6.5 Hz, 2H), 3.02 (t, J = 6.5 Hz, 2H); 19F NMR (DMSO-d6 /
Hexafluorobenzene):  -112.08 (s), -164.90 (s); ESI: m/z calculated for C20H17FN2O: 320.13,
found: 320.14. Anal. Calcd for C20H17 FN2O: C, 74.98; H, 5.35; N, 8.74. Found: C, 74.95; H,
5.39; N, 8.72.
2,3-Difluoro-N-[2-(6-Phenylpyridine-2-yl)ethyl]benzamide (DB2257, JD-1-30, 7e).
2,3-Difluorobenzoyl chloride (1.04 g, 5.87 mmol) was added to a mixture of 2-(6-phenylpyridin2-yl)ethan-1-amine (1.03 g, 5.20 mmol), triethylamine (0.800 ml, 5.72 mmol) and anhydrous
dichloromethane (20 ml). The reaction mixture was allowed to stir at room temperature overnight
under nitrogen atmosphere. The residue was purified by column chromatography on silica gel
with hexanes/ethyl acetate (9:1) as eluent providing 2,3-difluoro-N-[2-(6-phenylpyridine-2yl)ethyl]benzamide as a white solid (640 mg, 36%); mp = 79-80 C. 1H NMR (DMSO-d6 /D2O):
 8.01 (d, J = 7.0 Hz, 2H), 7.80-7.72 (m, 2 H), 7.44– 7.39 (m, 4 H), 7.31– 7.19 (m, 3 H), 3.68 (t,
J = 6.5 Hz, 2 H), 3.04 (t, J = 6.5 Hz, 2 H); 19F NMR (DMSO-d6 / Hexafluorobenzene):  -140.81,
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-143.13 (dd, J = 8.3 Hz), -164.90 (s); ESI: m/z calculated for C20H16F2N2O: 338.3500, found:
338.1309. Anal. Calcd for C20H16F2N2O: C, 71.00; H, 4.77; N, 8.28. Found: C, 70.73; H, 4.97;
N, 8.25.
2,6-Difluoro-N-[2-(6-phenylpyridine-2-yl)ethyl]benzamide (DB2225, JD-1-20, 7f).
2,6-difluorobenzoyl chloride (580 mg, 3.71 mmol) was added to a mixture of 2-(6-phenylpyridin2-yl)ethan-1-amine (651 mg, 3.28 mmol), triethylamine (0.500 ml, 3.61 mmol) and anhydrous
dichloromethane (15 ml). The reaction mixture was allowed to stir at room temperature overnight
under nitrogen atmosphere. The residue was purified by column chromatography on silica gel
with hexanes/ethyl acetate (4:1, 3:1, then 2:1) as eluent providing 2,6-difluoro-N-[2-(6phenylpyridine-2-yl)ethyl]benzamide as a light yellow solid (55 mg, 5%); mp =106.5 - 108.5 C.
1

H NMR (DMSO-d6 /D2O): d, J = 7.0 Hz, 2H), 7.78-7.72 (m, 2H), 7.47-7.40 (m, 4H),

7.23 (d, J = 7.5 Hz, 1H), 7.08 (t, J = 7.5 Hz, 2H), 3.68 (t, J = 6.5 Hz, 2H), 3.02 (t, J = 6.5 Hz,
2H); 19F NMR (DMSO-d6 / Hexafluorobenzene):  -116.46 (s), -164.90 (s); ESI: m/z calculated
for C20H16F2N2O: 338.3506, found: 338.1313. Anal. Calcd for C20H16 F2N2O: C, 71.00; H, 4.77;
N, 8.28. Found: C, 70.93; H, 5.07; N, 7.89.
2-Chloro-N-[2-(6-phenylpyridine-2-yl)ethyl]benzamide (DB2245, JD-1-27, 7g).

2-

Chlorobenzoyl chloride (628 mg, 3.59 mmol) was added to a mixture of 2-(6-phenylpyridin-2yl)ethan-1-amine (630 mg, 3.18 mmol), triethylamine (0.490 ml, 3.50 mmol) and anhydrous
dichloromethane (15 ml). The reaction mixture was allowed to stir at room temperature overnight
under nitrogen atmosphere. The residue was purified by column chromatography on silica gel
with hexanes/ethyl acetate (4:1) as eluent providing 2-chloro-N-[2-(6-phenylpyridine-2yl)ethyl]benzamide as a white solid (370 mg, 35%); mp = 106.5-108.5 C. 1H NMR (DMSO-d6
/D2O):  8.03 (d, J = 7.0 Hz, 2 H), 7.79-7.72 (m, 2 H), 7.47-7.36 (m, 5 H), 7.30-7.24 (m, 3 H),
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3.67 (t, J = 6.5 Hz, 2 H), 3.04 (t, J = 6.5 Hz, 2 H); 13C NMR (CDCl3):  165.6, 158.5, 155.7,
138.2, 136.5, 134.7, 129.9, 129.8, 129.2, 128.8, 128.0, 127.7, 125.9, 125.8, 121.0, 117.4, 38.1,
35.4; ESI: m/z calculated for C20H17ClN2O: 336.8100, found: 336.1108. Anal. Calcd for C20H17
FN2O + (0.16 OH2): C, 70.71; H, 5.14; N, 8.25. Found: C, 70.79; H, 5.06; N, 8.17.
2,6-Dichloro-N-[2-(6-phenylpyridine-2-yl)ethyl]benzamide (DB2234, JD-1-28, 7h).
2,6-Dichlorobenzoyl chloride (458 mg, 2.19 mmol) was added to a mixture of 2-(6-phenylpyridin2-yl)ethan-1-amine (490 mg, 2.47 mmol), triethylamine (0.380 ml, 2.72 mmol) and anhydrous
dichloromethane (15 ml). The reaction mixture was allowed to stir at room temperature overnight
under nitrogen atmosphere. The residue was purified by column chromatography on silica gel
with hexanes/ethyl acetate (4:1) as eluent providing 2,6-dichloro-N-[2-(6-Phenylpyridine-2yl)ethyl]benzamide as a white solid (460 mg, 50%); mp = 101.5-103.5 C. 1H NMR (DMSO-d6):
 8.02 (d, J = 7.0 Hz, 2H), 7.77-7.73 (m, 2 H), 7.54-7.38 (m, 6 H), 7.25 (d, J = 7.5 Hz, 1H), 3.72
(t, J = 6.5 Hz, 2 H), 3.05 (t, J = 6.5 Hz, 2 H); 13C NMR (DMSO-d6):  163.0, 158.1, 154.9, 138.3,
137.0, 136.1, 130.6, 130.3, 128.4, 128.1, 127.5, 126.1, 121.5, 117.4, 38.0, 36.5; ESI: m/z
calculated for C20H16Cl2N2O: 371.2598, found: 371.0718. Anal. Calcd for C20H16Cl2N2O: C,
64.701; H, 4.34; N, 7.55. Found: C, 64.58; H, 4.45; N, 7.48.
N-[2-(6-Phenylpyridine-2-yl)ethyl]cyclohexanecarboxamide (DB2230, JD-1-21, 7i).
Cyclohexanecarbonyl chloride (392 mg, 2.68 mmol) was added to a mixture of 2-(6phenylpyridin-2-yl)ethan-1-amine (470 mg, 2.37 mmol), triethylamine (0.360 ml, 2.61 mmol) and
dichloromethane (15 ml). The reaction mixture was allowed to stir at room temperature overnight
under nitrogen atmosphere. The residue was purified by column chromatography on silica gel
with hexanes/ethyl acetate (91:1, 4:1, then 3:1) as eluent providing N-[2-(6-phenylpyridine-2yl)ethyl]cyclohexanecarboxamide as an off-white solid (200 mg, 27%); mp = 114-116 C.

1

H
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NMR (DMSO-d6):  7.96 (d, J = 7.0 Hz, 2 H), 7.74-7.67 (m, 2 H), 7.46-7.37 (m, 3 H), 7.16 (d, J
= 7.0 Hz, 1H), 3.40 (t, J = 6.5 Hz, 2 H), 2.88 (t, J = 6.5 Hz, 2 H), 1.58-1.52 (m, 5 H); 1.21-1.03
(m, 5 H); 13C NMR (DMSO-d6):  174.5, 158.6, 154.9, 138.3, 136.9, 128.4, 128.1, 126.0, 121.3,
117.3, 43.5, 37.8, 37.0, 28.7, 24.9, 24.7; ESI: m/z calculated for C20H24N2O: 308.4200, found:
308.1967 . Anal. Calcd for C20H24N2O: C, 77.89; H, 7.84; N, 9.08. Found: C, 77.60; H, 7.83; N,
9.13.
N-[2-(6-Phenylpyridine-2-yl)ethyl]pyrolidine-1-carboxamide (DB2222, JD-1-18, 7j).
Pyrolidine carbonyl chloride (210 ml, 1.93 mmol) was added to a mixture of 2-(6-phenylpyridin2-yl)ethan-1-amine (340 mg, 1.71 mmol), triethylamine (260 ml, 1.88 mmol) and dichloromethane
(15 ml). The reaction mixture was allowed to stir at room temperature overnight under nitrogen
atmosphere. The residue was purified by column chromatography on silica gel with hexanes/ethyl
acetate/ethyl acetate + 5% MeOH (4:1, 1:1, then 1:1 w/ 5% MeOH) as eluent providing N-[2-(6phenylpyridine-2-yl)ethyl]pyrolidine-1-carboxamide as a light yellow solid (300 mg, 59%); mp =
104-106

C. 1H NMR (DMSO-d6):  8.08 (d, J = 7.2 Hz, 2 H), 7.82-7.45 (m, 2 H), 7.53-7.40

(m, 2 H), 7.21 (dd, J = 2.1 Hz, J = 4.1 Hz, 1 H), 6.20 (br s,1 H), 3.42 (q, J = 6.6 Hz, 2 H), 3.17
(t, J = 6.5, 4 H), 2.94 (t, J = 7.3, 2 H), 1.70-1.82 (m, 4 H); 13C NMR (DMSO-d6):  159.0, 156.0,
154.8, 138.3, 137.0, 128.4, 128.1, 126.0, 121.3, 117.2, 44.7, 39.6, 38.0, 24.5; ESI: m/z calculated
for C18H21N3O: 296.1756, found: 296.1763 . Anal. Calcd for C18H21N3O: C, 73.76; H, 7.49;
N,13.58. Found: C, 73.56; H, 7.40; N,13.37.
N-[2-(6-Phenylpyridine-2-yl)ethyl]piperidine-1-carboxamide (DB2221, JD-1 -17, 7k).
Piperidine carbonyl chloride (216 mg, 1.76 mmol) was added to a mixture of 2-(6-phenylpyridin2-yl)ethan-1-amine (310 mg, 1.56 mmol), triethylamine (240 ml, 1.72 mmol) and dichloromethane
(15 ml). The reaction mixture was allowed to stir at room temperature overnight under nitrogen
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atmosphere. The residue was purified by column chromatography on silica gel with hexanes/ethyl
acetate (4:1, then 1:1) as eluent providing N-[2-(6-phenylpyridine-2-yl)ethyl]piperidine-1carboxamide as a light yellow solid (240 mg, 50%); mp = 103.5-104.5 C. 1H NMR (DMSO-d6):
 8.08 (d, J = 7.2 Hz, 2H), 7.79 (m, 2 H), 7.51-7.42 (m, 3 H), 7.20 (dd, J = 6.2 Hz, J = 6.2 Hz, 1
H), 6.54 (t, J = 5.1 Hz, 1 H), 3.43 (q, J = 6.6 Hz, 2 H), 3.23 (t, J = 5.2 Hz, 4 H), 2.95 (t, J = 7.3
Hz, 2 H), 1.49 (m, 2 H), 1.41-1.32 (d, J = 4.0 Hz, 4 H); 13C NMR (DMSO-d6):  159.0, 156.7,
154.8, 138.3, 136.9,128.3, 128.1, 126.0, 121.3,117.2, 43.7, 39.8, 37.8, 27.8, 23.6; ESI: m/z
calculated for C19H23N3O: 310.1922, found: 310.1919. Anal. Calcd for C19H23N3O: C, 73.19; H,
7.17; N, 14.23. Found: C, 72.94; H, 7.16; N,14.01.
2-(6-(2-fluorophenyl)pyridin-2-yl)acetonitrile (JD-1-61, 8a) (2-fluorophenyl)boronic
acid (1.06 g, 7.60 mmol) was added to a solution of 2-(6-bromopyridin-2-yl) acetonitrile (1.00 g,
5.08 mmol) in 1,4-dioxane (15 ml) and de-airated with nitrogen. A 2 M aqueous solution of
Na2CO3 (7.62 mL, 15.24 mmol), ethanol (4 mL) and tetrakistriphenylphosphine palladium(0)
(0.294 g, 0.254 mmol) were added to the de-airated reaction mixture and allowed to stir overnight
at 100C under nitrogen atmosphere. The reaction mixture was cooled to room temperature,
separated with ethyl acetate, dried (MgSO4), filtered, and concentrated in vacuo. The product was
purified by column chromatography on silica gel using hexanes/ethyl acetate (9:1) as eluent to
provide 2-(6-(2-fluorophenyl)pyridin-2-yl)acetonitrile as a white solid (0.770 g, 3.63 mmol,
71.3%, 5) mp = 55.5 – 56.5C. 1H NMR (DMSO-d6):  7.97-7.92 (m, 2 H), 7.77, 7.74 (dd,, J =
7.8 Hz, 1H), 7.53-7.48 (m, 1 H), 7.41 (d, J = 7.6 Hz, 1H), 7.38-7.32 (m, 2 H), 4.29 (s, 2 H); 19F
NMR (DMSO-d6 / Hexafluorobenzene):  -119.40 (s), -164.90 (s); ESI-HRMS: m/z calculated
for C13H9FN2: 212.22, found: 212.0832.
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2-(6-(2-fluorophenyl)pyridin-2-yl)ethanamine (JD-1-62,

9a).

Lithium aluminum

hydride (0.131 g, 3.44 mmol) suspended in ethyl ether (10 mL) was added to a slurry of aluminum
chloride (0.459 g, 3.44 mmol) in ethyl ether (15 mL). The reaction mixture was stirred for 15
minutes after which 2-(6-(2-fluorophenyl)pyridin-2-yl)acetonitrile (0.729 g, 3.44 mmol),
dissolved in ethyl ether (25 mL), was added slowly and the reaction mixture was refluxed under
nitrogen atmosphere overnight. The reaction mixture was then cooled to room temperature and
quenched slowly with water dropwise (75 ml), basified with 5 N sodium hydroxide to pH 12,
extracted with ethyl ether (2 X 50 ml), dried (MgSO4), filtered, and concentrated in vacuo to
provide 2-(6-(2-fluorophenyl)pyridin-2-yl)ethanamine (0.532 g, 2.46 mmol, 71.5 %) as a yellow
oil which was used directly in the next step.
N-(2-(6-(2-fluorophenyl)pyridin-2-yl)ethyl)pyrolidine-1-carboxamide (DB2283, JD-167, 10a). Pyrolidine carbonyl chloride (202 ml, 1.91 mmol) was added to a mixture of 2-(6-(2fluorophenyl)pyridin-2-yl)ethanamine (0.365 g, 1.69 mmol), triethylamine (259 ml, 1.86 mmol)
and dichloromethane (30 ml). The reaction mixture was allowed to stir at room temperature
overnight under nitrogen atmosphere. The residue was purified by column chromatography on
silica

gel

with

hexanes/ethyl

acetate

(4:1,

1:1)

as

eluent

providing

N-(2-(6-(2-

fluorophenyl)pyridin-2-yl)ethyl)pyrolidine-1-carboxamide as an off white solid ( 0.315 g, 59.5%).
1H

NMR (DMSO-d6):  7.96-7.92 (m, 1H), 7.81 (t, J = 7.8 Hz, 1 H), 7.62-7.61 (m, 1 H), 7.50-

7.46 (m, 1 H), 7.35-7.30 (m, 2 H), 7.25 (d, J = 7.7 Hz, 1 H), 6.21 (t, J = 5.2 Hz, 1 H), 3.43-3.40
(m, 2 H), 3.16 (t, J = 6.4 Hz, 4 H), 2.95 (t, J = 7.2 Hz, 2 H), 1.75 (s, 4 H); 19F NMR (DMSO-d6 /
Hexafluorobenzene):  -119.60 (s), -164.90 (s); ESI: m/z calculated for C18H20FN3O: 313.37,
found: 313.1681 Anal. Calcd for C18H20FN3O: C, 68.99; H, 6.43; N, 13.41. Found: C, 69.28; H,
6.58; N, 13.41.
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N-(2-(6-(2-fluorophenyl)pyridin-2-yl)ethyl)piperidine-1-carboxamide (DB2282, JD-168, 10b). Piperidine carbonyl chloride (0.334g, 2.26 mmol) was added to a mixture of 2-(6-(2fluorophenyl)pyridin-2-yl)ethanamine (0.433 g, 2.00 mmol), triethylamine (307 ml, 2.20 mmol)
and dichloromethane (30 ml). The reaction mixture was allowed to stir at room temperature
overnight under nitrogen atmosphere. The residue was purified by column chromatography on
silica

gel

with

hexanes/ethyl

acetate

(4:1,

1:1)

as

eluent

providing

N-(2-(6-(2-

fluorophenyl)pyridin-2-yl)ethyl)piperidine-1-carboxamide as an off white solid ( 0.360 g, 55%).
1

H NMR (DMSO-d6):  7.94 (t, J = 7.8 Hz, 1H), 7.80 (t, J = 7.7 Hz, 1 H), 7.60 (d, J = 7.5 Hz, 1

H), 7.52-7.45 (m, 1 H), 7.34-7.29 (m, 2 H), 7.24 (d, J = 7.6 Hz, 1 H), 6.54 (t, J = 5.2 Hz, 1 H),
3.51-3.41 (m, 2 H), 3.21-3.20 (m, 4 H), 2.94 (t, J = 7.1 Hz, 2 H), 1.48-1.46 (m, 2 H), 1.22 (s, 4 H);
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F NMR (DMSO-d6 / Hexaflurobenzene):  -119.66 (s), -164.90 (s); ESI: m/z calculated for

C19H22FN3O: 327.40, found: 327.1825 Anal. Calcd for C19H22FN3O: C, 69.70; H, 6.77; N, 12.83.
Found: C, 69.844; H, 6.75; N, 12.90.
.2-(6-(3-fluorophenyl)pyridin-2-yl)acetonitrile (JD-1-36, 8b). (3-fluorophenyl)boronic
acid (1.59 g, 11.42 mmol) was added to a solution of 2-(6-bromopyridin-2-yl) acetonitrile (1.50 g,
7.61 mmol) in 1,4-dioxane (15 ml) and de-airated with nitrogen. A 2 M aqueous solution of
Na2CO3 (11.41 ml, 22.83 mmol), ethanol (4 mL) and tetrakistriphenylphosphine palladium(0)
(0.440 g, 0.381 mmol) were added to the de-airated reaction mixture and allowed to stir overnight
at 100C under nitrogen atmosphere. The reaction mixture was cooled to room temperature,
separated with ethyl acetate, dried (MgSO4), filtered, and concentrated in vacuo. The product was
purified by column chromatography on silica gel using hexanes/ethyl acetate (19:1) as eluent to
provide 2-(6-(3-fluorophenyl)pyridin-2-yl)acetonitrile as a white solid (0.880 g, 4.15 mmol,
54.5%, 5) mp = 38.0 – 39.0 C. 1H NMR (DMSO-d6):  7.94-7.87 (m, 4 H), 7.53-7.48 (m, 1 H),
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7.37 (d, J = 7.5 Hz, 1 H), 7.25 (t, J = 8.0 Hz, 1 H), 4.25 (s, 2 H);
Hexafluorobenzene):  -115.11 (s), -164.90 (s);
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F NMR (DMSO-d6 /

ESI-HRMS: m/z calculated for C13H9FN2:

212.22, found: 212.0828.
2-(6-(3-fluorophenyl)pyridin-2-yl)ethanamine (JD-1-40,

9b).

Lithium aluminum

hydride (0.150 g, 3.93 mmol) suspended in ethyl ether (10 mL) was added to a slurry of aluminum
chloride (0.524 g, 3.93 mmol) in ethyl ether (15 mL). The reaction mixture was stirred for 15
minutes after which 2-(6-(3-fluorophenyl)pyridin-2-yl)acetonitrile (0.834 g, 3.93 mmol),
dissolved in ethyl ether (25 mL), was added slowly and the reaction mixture was refluxed under
nitrogen atmosphere overnight. The reaction mixture was then cooled to room temperature and
quenched slowly with water dropwise (75 ml), basified with 5 N sodium hydroxide to pH 12,
extracted with ethyl ether (2 X 50 ml), dried (MgSO4), filtered, and concentrated in vacuo to
provide 2-(6-(3-fluorophenyl)pyridin-2-yl)ethanamine (0.682 g, 3.15 mmol, 80.2 %) as a yellow
oil which was used directly in the next step.
N-(2-(6-(3-fluorophenyl)pyridin-2-yl)ethyl)pyrolidine-1-carboxamide (DB2271, JD-141, 10c). Pyrolidine carbonyl chloride (214 mL, 2.02 mmol) was added to a mixture of 2-(6-(3fluorophenyl)pyridin-2-yl)ethanamine (0.387 mg, 1.79 mmol), triethylamine (275 mL, 1.97 mmol)
and dichloromethane (15 ml). The reaction mixture was allowed to stir at room temperature
overnight under nitrogen atmosphere. The residue was purified by column chromatography on
silica gel with hexanes/ethyl acetate (9:1, 4:1, 1:1, 1:1 + 1% MeOH) as eluent providing N-(2-(6(3-fluorophenyl)pyridin-2-yl)ethyl)pyrolidine-1-carboxamide as an off white solid ( 0.307 g, 0.980
mmol, 54.7%) mp = 112-113 C. 1H NMR (DMSO-d6):  7.93-7.87 (m, 2 H), 7.84-7.79 (m, 2 H),
7.23-7.22 (q, J = 14.2 Hz, 1 H), 7.27-7.22 (m, 2 H), 6.18 (t, J = 5.2 Hz, 1 H), 3.44-3.41 (m, 2 H),
3.17-3.16 (m, 4 H) 2.94 (t, J = 7.15 Hz, 2H), 1.74 (s, 4 H);
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F NMR (DMSO-d6 /
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Hexafluorobenzene):  -115.37 (s), -164.90 (s); ESI: m/z calculated for C18H20FN3O: 313.37,
found: 313.1669 Anal. Calcd for C18H20FN3O: C, 68.99; H, 6.43; N, 13.41. Found: C, 68.96; H,
6.35; N,13.37.
N-(2-(6-(3-fluorophenyl)pyridin-2-yl)ethyl)piperidine-1-carboxamide

(DB2270,

JD-1-42, 10d). Piperidine carbonyl chloride (0.215 g, 1.46 mmol) was added to a mixture of 2-(6(3-fluorophenyl)pyridin-2-yl)ethanamine (0.280 g, 1.29 mmol), triethylamine (200 mL, 1.42
mmol) and dichloromethane (15 ml). The reaction mixture was allowed to stir at room temperature
overnight under nitrogen atmosphere. The residue was purified by column chromatography on
silica

gel

with

hexanes/ethyl

acetate

(4:1,

2:3)

as

eluent

providing

N-(2-(6-(3-

fluorophenyl)pyridin-2-yl)ethyl)piperidine-1-carboxamide as an off white solid( 0.155 g, 0.473
mmol, 36.7%) mp = 115-116 C. 1H NMR (DMSO-d6):  7.93-7.87 (m, 2H), 7.83-7.77 (m, 2 H),
7.51 (q, J = 14.3 Hz, 1 H), 7.27-7.17 (m, 2 H), 6.52 (t, J = 5.2 Hz, 1 H), 3.42-3.40 (m, 2 H), 3.21
(m, 4 H), 2.93 (t, J = 7.2 Hz, 2 H), 1.47-1.46 (m, 2 H), 1.36-1.35 (m, 4 H); 19F NMR (DMSO-d6 /
Hexafluorobenzene): 

-115.37 (s), -164.90 (s); ESI: m/z calculated for C19H22FN3O: 327.40,

found: 327.1645 Anal. Calcd for C19H22FN3O: C, 69.70 H, 6.77; N, 12.83. Found: C, 69.58; H,
6.75; N,12.76.
2-(6-(4-fluorophenyl)pyridin-2-yl)acetonitrile (JD-1-49, 8c). (4-fluorophenyl)boronic
acid (1.94 g, 13.95 mmol) was added to a solution of 2-(6-bromopyridin-2-yl) acetonitrile (1.832
g, 9.30 mmol) in 1,4-dioxane (15 mL) and de-airated with nitrogen. A 2 M aqueous solution of
Na2CO3 (14.0 mL, 27.9 mmol), ethanol (4 mL) and tetrakistriphenylphosphine palladium(0) (0.537
g, 0.465 mmol) were added to the de-airated reaction mixture and allowed to stir overnight at
100C under nitrogen atmosphere. The reaction mixture was cooled to room temperature,
separated with ethyl acetate, dried (MgSO4), filtered, and concentrated in vacuo. The product was
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purified by column chromatography on silica gel using hexanes/ethyl acetate (19:1) as eluent to
provide 2-(6-(3-fluorophenyl)pyridin-2-yl)acetonitrile as a white solid (1.51 g, 7.12 mmol,
76.5 %) mp = 62.0 – 64.0 C. 1H NMR (DMSO-d6):  8.17-8.13 (m, 2 H), 8.05-8.00 (m, 2 H ),
7.36-7.30 (m, 3 H), 4.26 (s, 2 H);

19

F NMR (DMSO-d6 / Hexafluorobenzene):  -115.00 (s), -

164.90 (s); ESI-HRMS: m/z calculated for C13H9FN2: 212.22, found: 212.0828.
2-(6-(4-fluorophenyl)pyridin-2-yl)ethanamine (JD-1-51,

9c).

Lithium aluminum

hydride (0.252 g, 6.644 mmol) suspended in ethyl ether (10 mL) was added to a slurry of aluminum
chloride (0.886 g, 6.644 mmol) in ethyl ether (15 mL). The reaction mixture was stirred for 15
minutes after which 2-(6-(4-fluorophenyl)pyridin-2-yl)acetonitrile (1.41 g, 6.644 mmol),
dissolved in ethyl ether (25 mL), was added slowly and the reaction mixture was refluxed under
nitrogen atmosphere overnight. The reaction mixture was then cooled to room temperature and
quenched slowly with water dropwise (75 mL), basified with 5 N sodium hydroxide to pH 12,
extracted with ethyl ether (2 X 50 ml), dried (MgSO4), filtered, and concentrated in vacuo to
provide 2-(6-(4-fluorophenyl)pyridin-2-yl)ethanamine (1.2 g, 5.55 mmol, 83.5 %) as a yellow oil
which was used directly in the next step.
N-(2-(6-(4-fluorophenyl)pyridin-2-yl)ethyl)pyrolidine-1-carboxamide (DB2273, JD-152, 10e). Pyrolidine carbonyl chloride (330 mL, 3.07 mmol) was added to a mixture of 2-(6-(4fluorophenyl)pyridin-2-yl)ethanamine (0.587 mg, 2.71 mmol), triethylamine (420 mL, 2.98 mmol)
and dichloromethane (15 ml). The reaction mixture was allowed to stir at room temperature
overnight under nitrogen atmosphere. The residue was purified by column chromatography on
silica gel with hexanes/ethyl acetate (4:1, 1:1, 1:1 + 3% MeOH) as eluent providing N-(2-(6-(4fluorophenyl)pyridin-2-yl)ethyl)pyrolidine-1-carboxamide as an off white solid ( 0.420 g, 1.34
mmol, 49.5%) mp = 121.0-121.8 C. 1H NMR (DMSO-d6):  8.14-8.11 (m, 2 H), 7.80-7.75 (m,
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2 H), 7.30 (t, J = 8.9 Hz, 2 H), 7.19,7.18 (dd, J = 6.0 Hz, 1 H), 6.18 (t, J = 5.1 Hz, 1 H), 3.43 (q,
J = 13.00 Hz, 2 H), 3.16 (t, J = 6.4 Hz, 4 H), 2.94 (t, J = 7.3 Hz, 2 H), 1.76-1.73 (m, 4 H); 19F
NMR (DMSO-d6 / Hexafluorobenzene):  -115.69 (s), -164.90 (s); ESI: m/z calculated for
C18H20FN3O: 313.37, found: 313.1669 Anal. Calcd for C18H20FN3O: C, 68.99; H, 6.43; N, 13.41.
Found: C, 69.12; H, 6.61; N,13.37.
N-(2-(6-(4-fluorophenyl)pyridin-2-yl)ethyl)piperidine-1-carboxamide (DB2274, JD-153, 10f). Piperidine carbonyl chloride (0.472 g, 3.20 mmol) was added to a mixture of 2-(6-(4fluorophenyl)pyridin-2-yl)ethanamine (0.613 g, 2.83 mmol), triethylamine (434 mL, 3.11 mmol)
and dichloromethane (15 ml). The reaction mixture was allowed to stir at room temperature
overnight under nitrogen atmosphere. The residue was purified by column chromatography on
silica gel with hexanes/ethyl acetate (1:5, 7:3, 1:1) as eluent providing N-(2-(6-(4fluorophenyl)pyridin-2-yl)ethyl)piperidine-1-carboxamide as an off white solid( 0.593 g, 1.81
mmol, 64.0%) mp = 96.4 – 97.4 C. 1H NMR (DMSO-d6):  8.19-8.10 (m, 2H), 7.83-7.71 (m, 2
H), 7.30 (t, J = 8.8 Hz, 2 H), 7.18,7,17 (dd, J = 6.0 Hz, 1 H), 6.52 (t, J = 5.0 Hz, 1 H), 3.41 (q, J
= 12.75 Hz, 2 H), 3.21 (t, J = 5.2 Hz, 4 H), 2.92 (t, J = 7.2 Hz, 2 H), 1.47 (m, 2 H), 1.36-1.35 (m,
4 H); 19F NMR (DMSO-d6 / Hexafluorobenzene):  -115.73 (s), -164.90 (s); ESI: m/z calculated
for C19H22FN3O: 327.40, found: 327.1825 Anal. Calcd for C19H22FN3O: C, 69.70 H, 6.77; N,
12.83. Found: C, 69.91; H, 6.91; N,12.78.
2-(6-(3,4-fluorophenyl)pyridin-2-yl)acetonitrile

(JD-1-55,

8d).

(3,4-

fluorophenyl)boronic acid (1.20 g, 7.61 mmol) was added to a solution of 2-(6-bromopyridin-2yl) acetonitrile (1.00 g, 5.08 mmol) in 1,4-dioxane (15 mL) and de-airated with nitrogen. A 2 M
aqueous

solution

of

Na2CO3

(7.60

mL,

15.23

mmol),

ethanol

(4

mL)

and

tetrakistriphenylphosphine palladium(0) (0.294 g, 0.254 mmol) were added to the de-airated
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reaction mixture and allowed to stir overnight at 100C under nitrogen atmosphere. The reaction
mixture was cooled to room temperature, separated with ethyl acetate, dried (MgSO4), filtered,
and concentrated in vacuo. The product was purified by column chromatography on silica gel
using hexanes/ethyl acetate (19:1) as eluent to provide 2-(6-(3,4-fluorophenyl)pyridin-2yl)acetonitrile as a white solid (0.932 g, 4.05 mmol, 79.8 %, 5) mp = 53.9 – 54.9 C. 1H NMR
(DMSO-d6):):  8.15-8.10 (m, 1 H), 7.97-7.89 (m, 3 H ), 7.58-7.52 (m, 1 H), 7.38-7.37 (m, 1H),
4.26 (s, 2 H); 19F NMR (DMSO-d6 / Hexafluorobenzene):  -140.63, -140.80 (dd, J = 8.3 Hz), 164.90 (s); ESI-HRMS: m/z calculated for C13H8F2N2: 230.21, found: 231.0739.
2-(6-(3,4-fluorophenyl)pyridin-2-yl)ethanamine (JD-1-59,

9d).

Lithium aluminum

hydride (0.182 g, 4.80 mmol) suspended in ethyl ether (10 mL) was added to a slurry of aluminum
chloride (0.640 g, 4.80 mmol) in ethyl ether (15 mL). The reaction mixture was stirred for 15
minutes after which 2-(6-(3,4-fluorophenyl)pyridin-2-yl)acetonitrile (0.932 g, 4.05 mmol),
dissolved in ethyl ether (25 mL), was added slowly and the reaction mixture was refluxed under
nitrogen atmosphere overnight. The reaction mixture was then cooled to room temperature and
quenched slowly with water dropwise (75 mL), basified with 5 N sodium hydroxide to pH 12,
extracted with ethyl ether (2 X 50 ml), dried (MgSO4), filtered, and concentrated in vacuo to
provide 2-(6-(3,4-fluorophenyl)pyridin-2-yl)ethanamine (0.470 g, 2.01 mmol, 49.5 %) as a yellow
oil which was used directly in the next step.
N-(2-(6-(3,4-fluorophenyl)pyridin-2-yl)ethyl)piperidine-1-carboxamide (DB2280, JD1-62, 10g). Piperidine carbonyl chloride (0.444 g, 3.01 mmol) was added to a mixture of 2-(6(3,4-fluorophenyl)pyridin-2-yl)ethanamine (0.470 g, 2.01 mmol), triethylamine (310 ml, 2.21
mmol) and dichloromethane (15 ml). The reaction mixture was allowed to stir at room temperature
overnight under nitrogen atmosphere. The residue was purified by column chromatography on
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silica gel with hexanes/ethyl acetate (4:1, 1:1) as eluent providing N-(2-(6-(3,4fluorophenyl)pyridin-2-yl)ethyl)pyrolidine-1-carboxamide as an off white solid ( 0.273 g, 0.790
mmol, 39.3%) mp = 118 - 120 C. 1H NMR (DMSO-d6):  8.17-8.09 (m, 1 H), 8.00-7.94 (m, 1
H), 7.80-7.72 (m, 2 H), 7.56-7.50 (m, 1 H), 7.20 (d, J = 6.2 Hz, 1 H), 6.55-6.50 (m, 1 H), 3.553.50 (m, 2 H), 3.20 (d, J = 4.2 Hz, 4 H), 2.92-2.90 (m, 2 H), 1.46 (br s, 2 H), 1.34 (br s, 4H); 19F
NMR (DMSO-d6 / Hexafluorobenzene):  -140.65, -141.00 (dd, J = 8.3 Hz), -164.90 (s); ESI:
m/z calculated for C19H21F2N3O: 345.39, found: 345.1582 Anal. Calcd for C19H21F2N3O: C,
66.07; H, 6.13; N, 12.17. Found: C, 66.27; H, 6.16; N,12.20.

PART 2

1

Introduction

1.1 Disease Background
Leishmaniasis is a disease caused by unicellular eukaryotic parasitic protozoa called
Leishmania, a genus under the Trypanosomitida order (class Kinetoplastida). There are over 20
Leishmania species which cause the disease, most of which are zoonotic. Species are categorized
as “New World” species (Western Hemisphere) and “Old World” species (Eastern Hemisphere).
These include the L. mexicana complex with 3 main species (L. amazonensis, L. venezuelensis,
and (L. mexicana); the L. donovani complex with 2 species (L. infantum (known as L. chagasi in
the New World), and L. donovani); L. major; L. tropica; L. aethiopica; and the
subgenus Viannia with 4 main species (L. (V.) peruviana, (L. (V.) braziliensis, L. (V.) panamensis,
and L. (V.) guyanensis). The biological vectors of these parasites are various species of the sandfly,
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genera Phlebotomus and Lutzomyia. This disease is transmitted through the bite of an infected
female sandfly, genus Phlebotomus in the Old World, genus Lutzomyia in the New World, to
susceptible host.

8, 9, 10

Geographic distribution of the disease is worldwide, found in parts of more than 90
countries.

With the exception of Antarctica, Leishmania species have been reported on every

continent. This organism is primarily endemic to tropical and subtropical regions. Old World
leishmaniasis is found in regions of Africa (predominately Northern Africa tropical regions),
Southern Europe, Asia, and the Middle East; however, it is not found in the Pacific Islands or
Australia. New World leishmaniasis is found in Central America, South America, and regions of
Mexico; however, it is not found in Uruguay or Chile.

Human disease mainly occurs in the

Mediterranean Basin, South-East Asia, East Africa, Afro-Eurasia, and Latin America. While
20,000 to 30,000 deaths occur annually, disease incidence is estimated to be 1.3 million new cases
per year. The disease is considered a neglected tropical disease and affects the poorest people on
the planet. 10, 11
The disease presents in three main forms: cutaneous, mucocutaneous, and visceral.
Symptoms of the disease vary with the Leishmania species responsible for the infection. Certain
infections remain asymptomatic.
Visceral leishmaniasis (VL), also known as kala-azar, is caused by L. donovani and fatal if
untreated. Characterized by weight loss, irregular bouts of fever, anemia, and enlargement of the
spleen and liver, it is highly endemic in East Africa and the Indian subcontinent. With an estimated
200,000 to 400,000 new cases of VL occuring worldwide annually, over 90% of these cases occur
in six countries: India, Sudan, South Sudan, Brazil, Ethiopia, and Bangladesh. 8, 12
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Cutaneous leishmaniasis (CL), caused by L. major, is the most common form of
leishmaniasis causing serious disability and ulcers on exposed parts of the body which can leave
life-long scars. Disease incidence is estimated to be 0.7 million to 1.3 million new cases per year
with approximately 95% of CL cases occurring in the regions of the Mediterranean basin, the
Middle East, Central Asia, and the Americas; however, over two-third of CL new cases occur in
six countries: Colombia, Brazil, Algeria, Afghanistan, Syria, and Iran. 8, 13
Mucocutaneous Leishmaniasis, caused by L. braziliensis, is characterized by partial or total
mucous membrane destruction of the mouth, nose, and throat. Approximately 90% of
mucocutaneous leishmaniasis cases occur in Brazil, Peru and Bolivia. 8, 14
1.2 Current Drug Treatments
The current basis of treatment for leishmaniasis is chemotherapy, relying on a limited
selection of drugs with extreme limitations including excessive treatment cost, toxicity, problems
with routes of administration, and questionable efficacy in endemic populations. Antileishmanial
therapy has predominantly depended upon pentavalent antimonials including sodium
stibogluconate (Fig 5) and meglumine antimonite (Fig 6) for more than 70 years. 15

Figure 5 Structure of sodium stibogluconate.

Figure 6 Structure of Meglumine antimoniate.
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However, in parts of the world, resistance has limited the utility of antimonials16, in which
case Amphotericin B (Fig 7) and Pentamidine (Fig 8) are utilized as second line medications in
the event that antimonial drugs fail. 15

Figure 7 Structure of Amphotericin B.

Amphotericin B is a polyene antibiotic which has been found to be highly effective for the
treatment of antimonial resistant L. donovani and for cases of mucocutaneous leishmaniasis that
have not responded to antimonials17. The drug is given by i.v. infusion and has many side effects
including nephrotoxicity, anemia and hypokalemia. The high cost of the drug is another limiting
factor for use in developing countries.

Figure 8 Structure of Pentamidine.

In 1952, pentamidine was shown to be a relatively safe and not only an effective first-line
treatment for cutaneous leishmaniasis, but also, as a second-line treatment for visceral
leishmaniasis.18 Since the introduction of miltefosine (Fig 9) at the start of this century, there have
been no novel antileishmanial compounds approved for treatment in human beings. 15 A high cure

31

rate was reported in patients with visceral leishmaniasis by administrating the drug orally for 28
days.

19

Although it is the only drug which is given orally, it has a major limitation of being

teratogenic and this excludes its use in women of childbearing age.

Figure 9 Structure of Miltefosine.

Current treatment for this disease remains unsatisfactory as most of the drugs were
developed decades ago and do not meet current standards.20 Thus, the need for new drugs to treat
diseases caused by this parasite is evident.
1.3 Drug Discovery Strategies – Dual Targeting
In recent years, there has been growing use of the dual targeting approach to develop new
drugs. Due to problems with the use of conventional combination therapy (cocktail of drugs), a
strategy employed by clinicians to treat unresponsive patients, researchers have been motivated to
investigate molecular hybridization (MH) techniques. MH techniques employ the design of hybrid
drugs, essentially two drug pharmacophores that have been combined into one single molecule to
interact with multiple targets, or amplify activity on the bio target in a synergistic fashion, or
counterbalance known side-effects associated with one hybrid part. Pharmacophore hybridization
provides an attractive alternative to conventional therapy with the distinction that the two drugs
are covalently linked, yet administered as a single unit. 21
The MH design strategy essentially involves two or more known ligand sub-units (bioactive units) which are linked together either directly or with spacer units which may be rigid or
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flexible (Fig 10). The fusion of two or more recognized bioactive subunits leads to new hybrid
structural design, maintaining and even amplifying characteristics of the original prototypes. Dual
targeting and the development of hybrid molecules, with improved activity when compared to the
parent drugs, is a concept experiencing expanding usage as a drug design strategy.21

Figure 10 Molecular hybridization. 21

The MH design strategy has been successfully employed in a number of cancer
chemotherapy models. Tubulin inhibitors as single entities have proven successful as anticancer
agents and have provided researchers motivation to design hybrid structures. Tubulin inhibitor
based hybrids demonstrate significant anticancer potential. 21
Microtubules are constructed from repeating 𝛼/𝛽 subunits forming the spindle fibers.
Microtubules direct chromosomes during mitosis. Previous studies demonstrate that microtubule
assembly and disassembly can be blocked by a range of agents which bind to specific sites of the
β-tubulin subunit thereby disrupting the spindle fibers, arresting cells in mitosis and eventually
leading to apoptotic cell death. Presently, three binding sites have been defined: a) Taxane-
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binding pocket, b) Colchicine site close to the α/β interface, c) Area where the vinca alkaloids
bind.

The established literature shows within the class of Tubulin inhibitors, chalcones,

colchicines, vinca alkaloids, combrestatins and paclitaxel based hybrids have been designed and
present promising potential as anticancer agents.21
One such hybridization design for anticancer agents employs the linking of chalcones to
imidazolones, thus creating chalcone-imidazolones hybrids. Chalcones are known to interact with
tubulin at its colchicines binding site and exhibit potent toxicity to numerous cancer cell lines.
Imidazolones are recognized for their apoptosis inducing and Hdm 2 E3 ligase inhibiting ability.
The documented medicinal properties of chalcones and imidazolones led to the design of chalcone
linked imidazolones. The hybridized derivatives were evaluated for their anti-cancer activity
against 53 human tumor cell lines derived from nine different cancer types: lung, CNS, colon,
ovarian, renal, breast, leukemia, prostate, and melanoma. Many compounds presented good anticancer activity.21
Molecular hybridization techniques have also been used successfully to deliver new
antiprotozoal chemical agents. The clinical lifespan of drugs used as antiprotozoal agents,
especially monotherapeutic drugs, is almost invariably reduced by emerging drug resistance.
Therefore, the concept of combining two or more drugs with differing modes of action is an
attractive approach to provide hybrid molecules as the next generation antiprotozoal agents.22
Pentamidine and benzimidazole hybrid molecules have recently been reported to
demonstrate antileishmanial activity.

As previously mentioned, pentamidine, an aromatic

diamidine, is an effective first-line treatment for cutaneous leishmaniasis, but also, as a secondline treatment for visceral leishmaniasis. The unique structural architecture of benzimidazole is
recognized as an important scaffold in medicinal chemistry due to its many biological activities.
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The rational hybrid design strategy in this study conserved the central pentyldioxyphenyl spacer
in pentamidine while the terminal diamidine groups were replaced with a 5-substituted
benzimidazole sub-unit. The hybrids were tested against five species of parasites: Trichomonas
vaginalis, Leishmania mexicana, Giardia lamblia, Entamoeba histolytica, and Plasmodium
berghei. The bioactivity observed indicate enhancement of antiprotozoal activity with inclusion
of the benzimidazole into the pentamidine moeity, potentially due to the electron-donating capacity
of the benzimidazole sub-units.22
Current research reports that azole-arylimidamide (AIA) hybrids demonstrate
antileishmanial activity.23

In the past our laboratory focused on developing novel AIAs as

potential anti-parasitic drugs.23,24 This class of molecules, with DB766 (Fig 11) being the most
active, has had success as a treatment for Leishmaniasis in animals.25 A recent study suggests
CYP5122A1, an identified cytochrome P450 essential for ergosterol biosynthesis, virulence, drug
response, and survival in Leishmania, to be the target for AIA antileishmanial activity.26 Azole
antifungal agents are known to act as competitive inhibitors of CYP51, lanosterol 14demethylase, also an identified cytochrome P450, and also active against Leishmaniasis.27 Azoles
including posaconazole
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and ketoconazole29 (Fig 11) have been successfully used to treat

Leishmaniasis. Both of these classes of compounds inhibit different pathways in the cytochrome
P450 system and therefore have different modes of action, hence hybrid molecules of AIA and
azole units are of potential interest.26 This study will focus on the design and synthesis of AIAazole

hybrids

such

as

N-(4-(5-(4-((5-(1H-azole-1-yl)pentyl)oxy)phenyl)furan-2-

yl)phenyl)picolinimidamide hydrochloride analogues for the purpose of treating Leishmaniais.
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Figure 11 Structures of DB766, Ketoconazole, and Posaconazole.

1.4 Statement of Problem
In an effort to demonstrate proof of concept of antileishmanial activity of AIA-azole
hybrids, we decided to tether azole units from posaconazole and ketoconazole to the diphenylfuran
frame work of DB766. The overall shapes of AIAs and azoles are similar with nitrogen-containing
heterocycles bound to a linear or curved linker in each. It is hypothesized that a hybrid molecule
containing one arylimidamide terminal unit suitably linked to an azole unit may combine the
antileishmanial properties of individual azoles and AIAs. Thus, such molecules could interact
with azole target (CYP51) and the suggested AIA target (CYP5122A1)26. Initially, flexible linkers
of variable length will be used to attach the two pharmacophores to identify an effective geometry.
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2
2.1

Results and Discussion

Results
The synthesis of these prototype molecules employs a strategy of first attaching the linked

azole unit to the diphenylfuran frame work and then generating the arylimidamide unit which is
outlined in Scheme 3.
The first step employs a Stille coupling reaction between 4-bromonitrobenzene and 2-(trin-butylstannyl)furan in the presence of 0.05 equivalents of Pd(PPh3) using dioxane as the solvent
to afford compound (3). This product was then brominated utilizing 1.2 equivalents of NBS in
DMF at room temperature in the second step of this synthesis providing compound (4). Next,
dibromoalkanes (6) were added to a solution of the p-hydroxyphenylboronic pinacol ester (5) in
the presence of dry K2CO3, in acetone and vigorously stirred overnight to provide the 2-(4(bromoalkoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolanes (7).

Then, Suzuki coupling

between the 2-bromofuran (4) and 2-(4-(bromoalkoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2dioxaborolane (7) in the presence of 0.05 equivalents of Pd(PPh3)4 using a solvent mixture of
toluene-ethanol afforded compounds (8). Compounds (8) were then directly converted to the azole
analogues (9) in an arylation reaction with imidazole or triazole in the presence of NaH in DMF
at room temperature.

The 1-((4-(5-(4-nitrophenyl)furan-2-yl)phenoxy)alkyl)-1H-azole (9) was

reduced to yield the corresponding arylamine (10) in a hydrogenation reaction facilitated by 10%
PdC under 50 PSI of hydrogen gas. One equivalent of the aryl amine (10) was used directly in the
last step, cooled in an ice bath, to which 1.1 equivalents of S-(2-naphthylmethyl)-2-pyridyl
thioimidate hydrobromide was added and allowed to stir and slowly come to RT overnight. The
resulting product was then converted to the free base and then the corresponding HCl salt using
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freshly prepared ethanolic HCl solution, affording the target compounds (11) as hydrochloride
salts.
Scheme 3 Synthesis of N-(4-(5-(4-((1H-azol-1-yl)alkoxy)phenyl)furan-2-yl)phenyl)
picolinimidamide hydrochloride analogues

Reagents and conditions: (a) Pd(PPh3)4, dioxane, 90°C (b) NBS, DMF, rt (c) K2CO3, acetone, reflux (d)
Pd(PPh3)4, K2CO3, MeOH, toluene, 80°C (e) azole, NaH, DMF, rt (f) H2, PdC, EtOH-ETOAc (g) (i) S-(2naphthylmethyl-2-pyridylthiomidate hydeobromide, EtOH (ii) NaOh (iii) Ethanolic HCl

2.2 Discussion
Preliminary data for the four new hybrid compounds may be found in Table 2. It is
encouraging that the IC50 values are in the low micromolar range as this suggests that these
prototype molecules can be optimized to enhance activity. It is not prudent to engage in significant

38

SAR analysis with only four compounds. Nonetheless, it appears that in this set that imidazole is
superior to triazole for the azole portion of the hybrid. Clearly, a number of modifications
including the two pharmacophores and the linker are required in order to determine if this approach
will be fruitful.
Table 2 Biological Activity of N-(4-(5-(4-((1H-azol-1-yl)alkoxy)phenyl)furan-2-yl)phenyl)
picolinimidamide hydrochloride analogues against L. amazonensis30

Code 1

Code 2

n

X, Y

11a

DB2336

5

IC50 (M) versus
intracellular L. amazonensis
1.53 + 0.56

11b

DB2337

5

3.56 + 1.40

11c

DB2342

6

1.82 + 0.58

11d

DB2343

6

5.22 + 1.94

The IC50 values were generated in an in-vitro assay using the hybrids for L. amazonensis intracellular
amastigotes 30

3

Experimental

All commercial reagents were used without purification. Melting points were determined
on a Mel-Temp 3.0 apparatus and are uncorrected. TLC analysis was carried out on silica gel 60
F254 pre-coated aluminum sheets using UV light for detection.

1

H and 13C NMR were recorded

on a Bruker 400 MHz spectrometer using the indicated solvents. Mass spectra were obtained from
the Georgia State University Mass Spectrometry Laboratory, Atlanta, GA. Elemental analysis was
performed by Atlantic Microlab Inc., Norcross, GA.
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2-(4-nitrophenyl)furan (3) Tetrakistriphenylphosphine palladium (0.5mmol) was added
to a stirred mixture of the 2-(tributylstannyl) furan (11 mmol) and 1-bromo-4-nitrobenzene (10
mmol) in de-aireated dioxane (25 mL) under a nitrogen atmosphere. The vigorously stirred mixture
was heated at 90-100 °C for 24 h. The solvent was evaporated under reduced pressure, the resulting
solid was partitioned between ethyl acetate (200 mL) and 5 mL of concentrated ammonia, washed
with water, passed through celite, dried over sodium sulfate and evaporated. Purification was by
column chromatography on silica gel, using hexanes/ethyl acetate (93/7, v/v). The solid attained
was then recrystallized from hexanes/ethyl acetate. Yellow solid, yield (68 %); mp 134-135 oC 31,
mp 131-132; 1HNMR (DMSO-d6) δ 6.71 (d, J = 3.6 Hz, 1H), 7.02 (br s, 1H), 7.23 (d, J = 3.6 Hz,
1H), 7.90 (d, J = 8.8 Hz, 2H), 7.98 (d, J = 8.8 Hz, 2H).
2-bromo-5-(4-nitrophenyl)furan (4) N-bromosuccinimide (2.13 gm, 12 mmol) was
added portion-wise to a stirred solution of the previous nitro comp (10 mmol) in
dimethylformamide (20 ml). The reaction mixture was stirred at room temperature for 12 h then
poured onto cold water, the precipitate was collected and dried. Purification by column
chromatography on silica gel, using hexanes/ethyl acetate (95/5, v/v). Yellow solid, yield (96 %);
mp 141-143 oC; 1HNMR (DMSO-d6) δ 6.83 (d, J = 3.6 Hz, 1H), 7.35 (d, J = 3.6 Hz, 1H), 7.90 (d,
J =8.8 Hz, 2H), 8.26 (d, J =8.8 Hz, 2H); HRMS: m/z calculated for C10H7BrNO3: 267.9609, found:
267.9602 (M+ +1).
General

Procedure:

2-(4-(bromoalkoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-

dioxaborolane (7) Dibromoalkanes (36 mmol) were added to a solution of the phydroxyphenylboronic acid ester (6 mmol) and dry K2CO3 (12 mmol) in anhydrous acetone (30
ml) under a nitrogen atmosphere. The vigorously stirred mixture was allowed to reflux for 48 h,
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K2CO3 was filtered and washed with acetone (5 ml) then the combined filterate was evaporated
under reduced pressure. Purification was by column chromatography on silica gel, using
hexanes/ethyl acetate (93/7, v/v).
2-(4-((5-bromopentyl)oxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (7a)White
solid (66 %) mp 99-101 oC, 1HNMR (CDCl3) δ 1.35 (s, 12 H), 1.62-1.65 (m, 2 H), 1.82-1.85 (m,
2 H), 1.94-1.97 (m, 2 H), 3.45 (t, J =6 Hz, 2 H), 4.03 (t, J = 6 Hz, 2 H), 6.91 (d, J = 8.4 Hz, 2H),
7.76 (d, J =8.4 Hz, 2 H); HRMS: m/z calculated for C17H27 BBrO3: 369.1237, found: 369.1264
(M+ +1);
2-(4-((6-bromohexyl) oxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (7b)White
solid (75 %) mp 98-99 oC; 1HNMR (CDCl3, ppm): δ 7.77 (d, J = 8.4 Hz, 2H), 6.90 (d, 2H), 4.024.00 (t, J = 6.6 Hz, 2H), 3.49-3.44 (t, J = 6.9 Hz, 2H), 1.91-1.82 (m, 4H), 1.54-1.50 (m, 4H), 1.38
(s, 12H).
General Procedure: 2-(4-(bromoalkoxy)phenyl)-5-(4-nitrophenyl)furan (8) 2.3 ml
deaireated 2 M aqueous solution of K2CO3 and p-hydroxyphenyl boronic acid ester (7) (2.73
mmol) in 5 ml deaireated methanol were added to a stirred solution of 2-bromo-5-(4nitrophenyl)furan (2.28 mmol), and tetrakistriphenylphosphine palladium (0.114 mmol) in
deaireated toluene (25 mL) under a nitrogen atmosphere. The vigorously stirred mixture was
warmed to 80 °C for 24 h. The solvent was evaporated under reduced pressure. Purification was
by column chromatography on silica gel, using hexanes/ethyl acetate (90/10, v/v).
2-(4-((5-bromopentyl)oxy)phenyl)-5-(4-nitrophenyl)furan (8a) Orange solid, yield (62
%); mp 70-71 oC; 1HNMR (DMSO-d6) δ 1.67-1.68 ( m, 2 H), 1.85 (m, 2 H), 1.96-2.00 (m, 2 H),
3.47 (br s, 2 H), 4.02 (br s, 2 H), 6.66 (br s, 1 H), 6.94-6.96 (m, 3 H), 7.68 (d, J =8.4 Hz, 2H), 7.78
(d, J =8 Hz, 2H), 8.22 (d, J = 8 Hz, 2H).
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2-(4-((6-bromohexyl)oxy)phenyl)-5-(4-nitrophenyl)furan (8b) Yellow solid, yield (59
%); mp 76-77 oC; 1HNMR (DMSO-d6) δ 1.46 ( m, 4 H), 1.82 (br s, 2 H), 1.84 (br s, 2 H), 3.55 (t,
J =6.4 Hz, 2H), 4.03 (t, J =6.4 Hz, 2H), 7.03-7.05 (m, 3 H), 7.40 (d, J = 3.6 Hz, 1 H), 7.80 (d, J
=8.8 Hz, 2H), 8.03 (d, J =8.8 Hz, 2H), 8.28 (d, J = 8.8 Hz, 2H); HRMS: m/z calculated for C22H23
BrNO4: 444.0810, found: 444.0799 (M+ +1).
General Procedure: 1-((4-(5-(4-nitrophenyl)furan-2-yl)phenoxy)alkyl)-1H-azole (9)
The previous bromoalkoxy (8) compounds (2 mmol) were added to a solution of the azole (2
mmol) and NaH (2.5 mmol) in dry DMF (10 ml) under a nitrogen atmosphere. The reaction mixture
was stirred at room temperature for 12 h, then poured on ice-water (50 ml), filtered and dried.
Purification by recrystallization from ethyl acetate/ hexanes.
1-(5-(4-(5-(4-nitrophenyl)furan-2-yl)phenoxy)pentyl)-1H-imidazole (9a) Orange solid,
yield (73 %); mp 61-62 oC; 1HNMR (CDCl3) δ 1.28 (br s, 2H), 1.60-1.80 (m, 4H), 4.01-4.03 (m,
2 H), 4.23-4.24 (m, 2 H), 6.81 (d, J = 3.6 Hz, 1 H), 7.94-6.97 (m, 3 H), 7.11 (br s, 1H), 7.61 (br s,
1H), 7.70 (d, J = 8.8 Hz, 2 H), 7.84 (d, J = 8.8 Hz, 2H), 8.03 (br s, 1H), 8.27 (d, J = 8.8 Hz, 2H);
HRMS: m/z calculated for C24H24N3O4: 418.1785, found: 418.1767 (M+ +1).
1-(5-(4-(5-(4-nitrophenyl)furan-2-yl)phenoxy)pentyl)-1H-1,2,4-triazole (9b) Orange
solid, yield (67 %); mp 69-70 oC; 1HNMR (CDCl3) δ 1.27 (br s, 2H), 1.86-1.87 (m, 2H), 2.00-2.02
(m, 2 H), 4.01-4.03 (m, 2 H), 4.23-4.24 (m, 2 H), 6.49 (br s, 1H), 6.95-6.97 (m, 3 H), 7.71 (d, J =
8 Hz, 2H), 7.84 (d, J = 8.8 Hz, 2H), 7.98 (br s, 1H), 8.09 (br s, 1H), 8.28 (d, J = 8.8 Hz, 2H);
HRMS: m/z calculated for C23H23N4O4: 419.1719, found: 419.1706 (M+ +1).
1-(6-(4-(5-(4-nitrophenyl)furan-2-yl)phenoxy)hexyl)-1H-imidazole (9c) Orange solid,
yield (63 %); mp 63-64 oC; 1HNMR (DMSO-d6) δ 1.25-127 (m, 2H), 1.42-1.44 (m, 2H), 1.69-1.72
(m, 4 H), 3.94-3.97 (m, 4 H), 6.88 (br s, 1H), 7.01-7.04 (m, 3 H), 7.16 (br s, 1H), 7.41 (d, J = 3.6
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Hz, 1H), 7.62 (br s, 1H), 7.79 (d, J = 8.8 Hz, 2H), 8.02 (d, J = 8.8 Hz, 2H), 8.27 (d, J = 8.8 Hz,
2H); HRMS: m/z calculated for C25H26N3O4: 432.1923, found: 432.1909 (M+ +1).
1-(6-(4-(5-(4-nitrophenyl)furan-2-yl)phenoxy)hexyl)-1H-1,2,4-triazole (9d) Orange
solid, yield (71 %); mp 68-69 oC; 1HNMR (DMSO-d6) δ 1.17-1.23 (m, 2H), 1.28-1.30 (m, 2H),
1.70-1.73 (m, 4 H), 3.99 (t, J = 6.4 Hz, 2H), 4.19 (t, J = 6.4 Hz, 2H), 7.02-7.04 (m, 3 H), 7.41 (d,
J = 3.6 Hz, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.95 (br s, 1 H), 8.03 (d, J = 8.8 Hz, 2H), 8.28 (d, J =
8.8 Hz, 2H), 8.52 (br s, 1 H); HRMS: m/z calculated for C24H25N4O4: 433.1870, found: 433.1853
(M+ +1).
General Procedure: 4-(5-(4-(1H-azol-1-yl)alkoxy)phenyl)furan-2-yl)aniline (10) To a
de-aireated solution of the previous nitrocompound (5 mmol) in ethyl acetate/ethanol (60ml: 20ml)
mixture was added Pd/C (10 %) (0.2 gm). Stirring in a parr hydrogenator under 50 PSI until the
uptake of hydrogen ceased, the consumption of hydrogen gave a clear solution. The solution was
filtered through celite, and the solvent was removed under reduced pressure, the residue formed
was used directly in the next step without further purification. Since the amine is easily oxidized,
it is imperative to proceed with the next step immediately.
4-(5-(4-((5-(1H-imidazol-1-yl)pentyl)oxy)phenyl)furan-2-yl)aniline (10a) White solid,
yield (89 %); mp 59-61 oC; 1HNMR (DMSO-d6) δ 1.37 (br s, 2 H), 1.75 (br s, 4 H), 3.98 (br s, 4
H), 5.34 (s, 2 H), 6.62 (m, 3 H), 6.79 (br s, 1 H), 6.88 (br s, 1 H), 6.96 (d, J = 7.6 Hz, 2 H), 7.17
(br s, 1 H), 7.44 (d, J = 7.6 Hz, 2 H), 7.63-7.65 (m, 3 H); HRMS: m/z calculated for C24H26N3O2:
388.2025, found: 388.2029 (M+ +1).
4-(5-(4-((5-(1H-1,2,4-triazol-1-yl)pentyl)oxy)phenyl)furan-2-yl)aniline (10b) White
solid, yield (92 %); mp 61-62 oC; 1HNMR (DMSO-d6) δ 1.37 (br s, 2 H), 1.74 (br s, 2 H), 1.85 (br
s, 2 H), 3.98 (br s, 2 H), 4.21 (br s, 2 H), 5.32 (s, 2 H), 6.62 (m, 3 H), 6.79 (br s, 1 H), 6.96 (d, J =
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7.2 Hz, 2 H), 7.43 (d, J = 7.2 Hz, 2 H), 7.64 (d, J = 7.6 Hz, 2 H), 7.96 (br s, 1 H), 8.53 (br s, 1 H);
HRMS: m/z calculated for C23H25N4O2: 389.1978, found: 389.1964 (M+ +1).
4-(5-(4-((6-(1H-imidazol-1-yl)hexyl)oxy)phenyl)furan-2-yl)aniline (10c) White solid,
yield (97 %); mp 51-52 oC; 1HNMR (DMSO-d6) δ 1.40 (br s, 4 H), 1.51 (br s, 4 H), 3.97-4.00 (m,
4 H), 4.79 (s, 2 H), 6.52 (d, J = 3.2 Hz, 1 H), 6.57 (br s, 1 H), 6.73 (d, J = 8.4 Hz, 2 H), 6.91 (d, J
= 8.4 Hz, 2 H), 7.28 (br s, 2 H), 7.54-7.56 (m, 3 H), 7.66 (d, J = 8.4 Hz, 2 H); HRMS: m/z calculated
for C25H28N3O2: 402.2182, found: 402.2185 (M+ +1).
4-(5-(4-((6-(1H-1,2,4-triazol-1-yl)hexyl)oxy)phenyl)furan-2-yl)aniline

(10d)

White

solid, yield (97 %); mp 51-52 oC; 1HNMR (DMSO-d6) δ 1.28 (br s, 2 H), 1.44 (br s, 2 H), 1.701.80 (m, 4 H), 3.97 (br s, 2 H), 4.18 (br s, 2 H), 5.33 (s, 2 H), 6.60-6.62 (m, 3 H), 6.79 (br s, 1 H),
6.96 (d, J = 8 Hz, 2 H), 7.45 (d, J = 7.6 Hz, 2 H), 7.66 (d, J = 8 Hz, 2 H), 7.95 (br s, 1 H), 8.52 (s,
1 H); HRMS: m/z calculated for C24H27N4O2: 403.2129, found: 403.2122 (M+ +1).
General Procedure:

N-(4-(5-(4-((1H-azol-1-yl)alkoxy)phenyl)furan-2-yl)phenyl)

picolinimidamide hydrochloride (11) S-(2-Naphthylmethyl)-2-pyidyl thioimidate hydrobromide
(1.87 mmol) was added to a cooled solution of the amino azoles (10) (1.7 mmol) in dry ethanol
(30 mL) in an ice bath. The mixture was stirred at room temperature for overnight. The organic
solvent was evaporated under reduced pressure to yield an oil product. Dry ether (100 mL) was
added to the oil and the mixture was stirred at room temperature for 1 h. A precipitate formed and
was filtered and washed with dry ether. The solid was dissolved in ethanol (2 ml); the solution was
cooled to 0 oC in an ice bath and 10% NaOH was added until pH reached approximately 10. The
free base was extracted with ethyl acetate (3 × 50 mL). The organic layer was washed with distilled
water, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The
resulting solid freebase was treated with dry hexanes and then filtered. The free base was
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suspended in dry ethanol (20 mL) and cooled to 0 oC in an ice bath. Freshly prepared ethanolic
HCl solution (2 ml) was added to the suspension and the mixture was stirred at room temperature
for overnight. The resulting red solution was concentrated under reduced pressure to yield a. The
solid was recrystallized twice from dry ethanol and dry ether and filtered.
N-(4-(5-(4-((5-(1H-imidazol-1-yl)pentyl)oxy)phenyl)furan-2-yl)phenyl)
picolinimidamide hydrochloride (11a) Yellow solid, yield (55 %); mp 80-82 oC dec.; 1HNMR
(DMSO-d6) δ 1.39-1.40 (m, 2 H), 1.76-1.77 (m, 2 H), 1.88-1.92 (m, 2 H), 4.01-4.04 (m, 4 H), 6.97
(d, J = 3.2 Hz, 1 H), 7.02 (d, J = 8.4 Hz, 2 H), 7.18 (d, J = 3.2 Hz, 1 H), 7.22 (br s, 1 H), 7.38 (s,
1 H), 7.48 (s, 1 H), 7.55 (d, J = 8.4 Hz, 2 H), 7.71 (br s, 2 H), 7.77 (d, J = 8.4 Hz, 2 H), 7.84 (d, J
= 8.4 Hz, 2 H), 7.97 (d, J = 8 Hz, 2 H), 8.21-8.25 (m, 1 H), 8.52 (d, J = 8 Hz, 1 H), 11.88 (s, 1 H);
CNMR (DMSO-d6) δ 24.4, 27.9, 28.4, 55.4, 66.9, 106.1, 108.8, 114.4, 122.2, 123.8, 124, 124.4,
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124.6, 125.9, 128, 128.7, 129.6, 132.6, 137.8, 143.9, 148.5, 149.2, 150.5, 152.8, 157.9, 158.8;
HRMS: m/z calculated for C30H30N5O2: 492.2400, found: 492.2390 (base M+ +1); Anal. Calcd.
For C30H30N5O2. 2 HCl. 1.75 H2O: C, 60.45; H, 5.83; N, 11.75; Found: C, 60.14; H, 5.61; N, 11.39.
N-(4-(5-(4-((5-(1H-1,2,4-triazol-1-yl)pentyl)oxy)phenyl)furan-2-yl)phenyl)
picolinimidamide hydrochloride (11b) Yellow solid, yield (49 %); mp 89-91 oC dec.; 1HNMR
(DMSO-d6) δ 1.38-1.40 (m, 2 H), 1.76-1.79 (m, 2 H), 1.88-1.89 (m, 2 H), 4.00 (d, J = 6 Hz, 2 H),
4.28 (d, J = 6 Hz, 2 H), 6.97 (d, J = 3.2 Hz, 1 H), 7.01 (d, J = 8.8 Hz, 2 H), 7.18 (d, J = 3.2 Hz, 1
H), 7.55 (d, J = 8.4 Hz, 2 H), 7.76 (d, J = 8.4 Hz, 2 H), 7.87 (br s, 1 H), 7.97 (d, J = 8 Hz, 2 H),
8.23 (br s, 2 H), 8.50 (d, J = 7.6 Hz, 1 H), 8.90 (m, 2 H), 9.37 (s, 1 H), 10.14 (s, 1 H), 11.86 (s, 1
H); 13CNMR (DMSO-d6) δ 24.4, 27.8, 29, 53.2, 66.1, 106.1, 108.9, 114.3, 122.9, 123.8, 124, 124.5,
124.6, 126.7, 128.3, 128.7, 129.6, 132.6, 138, 143.9, 148.9, 149.2, 150.5, 152.8, 157.9, 159;
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HRMS: m/z calculated for C29H29N6O2: 493.2352, found: 493.2338 (base M+ +1); Anal. Calcd.
For C29H28N6O2. 2 HCl. 1.25 H2O: C, 59.24; H, 5.57; N, 14.29; Found: C, 59.02; H, 5.31; N, 13.98.
N-(4-(5-(4-((6-(1H-imidazol-1-yl)hexyl)oxy)phenyl)furan-2-yl)phenyl)
picolinimidamide hydrochloride (11c) Yellow solid, yield (47 %); mp 78-80 oC dec.; 1HNMR
(DMSO-d6) δ 1.29-1.40 (m, 4 H), 1.71-1.81 (m, 4 H), 3.99 (br s, 2 H), 4.23-4.30 (m, 2 H), 6.977.00 (m, 3 H), 7.17 (br s, 1 H), 7.55 (br s, 2 H), 7.70-7.76 (m, 4 H), 7.86 (br s, 2 H), 7.95 (br s, 2
H), 8.21 (br s, 1 H), 8.59 (br s, 1 H), 8.88 (br s, 1 H), 9.32 (s, 1 H), 10.19 (s, 1 H), 11.96 (s, 1 H);
CNMR (DMSO-d6) δ 24.1, 25.1, 27.9, 28.1, 54, 65.3, 106.1, 108.8, 113.6, 122.7, 123.8, 124,
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124.4, 124.6, 125.6, 128.7, 129, 129.6, 132.6, 138.6, 143.9, 148.6, 149.7, 150.5, 152.1, 157.9,
159.3; HRMS: m/z calculated for C31H32N5O2: 506.2556, found: 506.2549 (base M+ +1); Anal.
Calcd. For C31H31N5O2. 2 HCl. 2 H2O: C, 60.59; H, 6.07; N, 11.40; Found: C, 60.34; H, 6.02; N,
11.13.
N-(4-(5-(4-((6-(1H-1,2,4-triazol-1-yl)hexyl)oxy)phenyl)furan-2-yl)phenyl)
picolinimidamide

hydrochloride (11d) Yellow solid, yield (44 %); mp 81-83 oC dec.; 1HNMR

(DMSO-d6) δ 1.29-1.40 (m, 4 H), 1.70-1.80 (m, 4 H), 3.99 (br s, 2 H), 4.25 (br s, 2 H), 6.97 (s, 1
H), 7.02 (d, J = 7.2 Hz, 2 H), 7.18 (br s, 1 H), 7.56 (d, J = 7.2 Hz, 2 H), 7.76 (d, J = 7.2 Hz, 2 H),
7.86, (br s, 1 H), 7.97 (d, J = 7.2 Hz, 2 H), 8.22 (br s, 1 H), 8.32 (s, 1 H), 8.59 (d, J = 7.2 Hz, 1 H),
8.89 (s, 1 H), 9.07 (s, 1 H), 9.40 (s, 1 H), 10.19 (s, 1 H), 11.96 (s, 1 H); 13CNMR (DMSO-d6) δ
24.1, 25.2, 27.8, 28.3, 55.8, 66.9, 106, 108.1, 114.4, 122.3, 123.6, 123.9, 124.5, 124.6, 126.7,
128.5, 128.7, 129.6, 132.6, 138.4, 143.9, 146.1, 149.2, 150.5, 152.9, 157.2, 158.8; HRMS: m/z
calculated for C30H31N6O2: 507.2503, found: 507.2492 (base M+ +1); Anal. Calcd. For
C30H30N6O2. 2 HCl. 2.5 H2O: C, 57.69; H, 5.97; N, 13.46; Found: C, 57.36; H, 5.88; N, 13.29.
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